Galectin Therapeutics (GALT) Cash from Financing Activities (2010 - 2026)

Galectin Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $257000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $257000.0; the TTM figure through Mar 2026 stood at $26.7 million (up 25.93% YoY), while the FY2025 annual figure was $26.5 million, down 15.22% from the prior year.
• Cash from Financing Activities was $257000.0 for Q1 2026 at Galectin Therapeutics, down from $12.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $12.9 million in Q2 2025 to a low of $257000.0 in Q1 2026.
• Historically, Cash from Financing Activities has averaged $8.3 million across 5 years, with a median of $10.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 91.49% in 2024, then surged 1337.96% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then tumbled by 91.49% to $851000.0 in 2024, then soared by 1337.96% to $12.2 million in 2025, then sank by 97.9% to $257000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $257000.0 (Q1 2026), $12.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.